Trial Profile
A Randomized, Double-Blind, Multi-Center,Study Evaluating the Effects of Eplerenone Versus Placebo on Ventricular Remodeling in Patient's With Left Ventricular Systolic Dysfunction (EF less than 35 percent) and Mild to Moderate Heart Failure
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Dec 2020
Price :
$35
*
At a glance
- Drugs Eplerenone (Primary)
- Indications Heart failure; Left ventricular dysfunction
- Focus Pharmacodynamics
- Acronyms REMODEL
- Sponsors Pfizer
- 18 Mar 2010 Results published in Circulation.
- 01 Sep 2006 Status change
- 19 Oct 2005 New trial record.